Results 91 to 100 of about 2,856,528 (208)

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]

, 2014
Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie, Hamers, Claude, Hudelet, Pascal, Nunes, Sandro Filipe, Palmarini, Massimo, Ratinier, Maxime, Shaw, Andrew   +6 more
core   +2 more sources

Immunogenicity of experimental DNA vaccines encoding hemagglutinin and hemagglutinin stalk of influenza A (H5N8) virus

Сибирский научный медицинский журнал
Avian influenza A virus subtype H5 is widespread in the bird population, and there is a risk of its transmission to humans, therefore, it is necessary to develop an effective vaccine to prevent virus spread.
V. R. Litvinova, N. B. Rudometova, L. A. Kisakova, D. N. Kisakov, V. A. Yakovlev, E. V. Tigeeva, M. B. Borgoyakova, K. I. Ivanova, V. Yu. Marchenko, T. N. Ilyicheva, L. I. Karpenko, A. P. Rudometov, A. A. Ilyichev   +12 more
doaj   +1 more source

Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines

Vaccines, 2019
DNA vaccines present one of the most cost-effective platforms to develop global vaccines, which have been tested for nearly three decades in preclinical and clinical settings with some success in the clinic.
Ashish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans, Branka Grubor-Bauk   +5 more
doaj   +1 more source

DNA Vaccines: Recent Developments and the Future

Vaccines, 2014
This special issue is focused on DNA vaccines, marking the two decades since the first demonstration of pre-clinical protection was published in Science (Ulmer et al.; Heterologous protection against influenza by injection of DNA encoding a viral protein.
B. Wahren, Margaret A. Liu
semanticscholar   +1 more source

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Science, 2020
Prototype DNA vaccines for SARS-CoV-2 The development of a vaccine to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent biomedical need. Yu et al.
Jingyou Yu, Lisa H. Tostanoski, Lauren Peter, N. Mercado, K. McMahan, S. Mahrokhian, Joseph P. Nkolola, Jinyan Liu, Zhenfeng Li, A. Chandrashekar, David R. Martinez, C. Loos, C. Atyeo, S. Fischinger, J. Burke, Matthew D. Slein, Yuezhou Chen, Adam Zuiani, Felipe J. N. Lelis, M. Travers, S. Habibi, Laurent Pessaint, Alex Van Ry, Kelvin Blade, Renita Brown, Anthony Cook, Brad Finneyfrock, A. Dodson, Elyse Teow, Jason Velasco, R. Zahn, F. Wegmann, E. Bondzie, Gabriel Dagotto, M. Gebre, Xuan He, C. Jacob-Dolan, Marinela Kirilova, N. Kordana, Zijin Lin, Lori F. Maxfield, Felix Nampanya, Ramya Nityanandam, John D. Ventura, H. Wan, Yongfei Cai, Bing Chen, A. Schmidt, D. Wesemann, R. Baric, G. Alter, H. Andersen, M. Lewis, D. Barouch   +53 more
semanticscholar   +1 more source

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

Journal of Infectious Diseases, 2014
Background Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents.
Uzma N. Sarwar, Pamela J M Costner, M. Enama, N. Berkowitz, Zonghui Hu, C. S. Hendel, S. Sitar, Sarah H. Plummer, S. Mulangu, R. Bailer, R. Koup, J. Mascola, G. Nabel, N. Sullivan, B. Graham, J. Ledgerwood   +15 more
semanticscholar   +1 more source

Cancer vaccines: uses of HLA transgenic mice compared to genetically modified mice [PDF]

, 2008
Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the discovery of peptides ...
McArdle, SE
core  

Challenges to the development of antigen-specific breast cancer vaccines [PDF]

, 2001
Continued progress in the development of antigen-specific breast cancer vaccines depends on the identification of appropriate target antigens, the establishment of effective immunization strategies, and the ability to circumvent immune escape mechanisms.
B Thurner, BJ Van den Eynde, D Jäger, DH Kaplan, Dirk Jäger, DR Leach, E Jäger, E Jäger, FO Nestle, GP Murphy, IB Runnebaum, JJ Mule, JW Hodge, K Chikamatsu, M Marchand, MA Morse, Matthew J Scanlan, MJ Scanlan, ML Disis, ML Disis, NP Restifo, P van der Bruggen, PA Lodge, RF Wang, S Morel, S Wojtowicz-Praga, T Soussi, U Sahin, U Sahin, Y Kawakami, Y Paterson, YT Chen, YT Chen   +32 more
core   +2 more sources

Strategies and hurdles using DNA vaccines to fish

Veterinary Research, 2014
DNA vaccinations against fish viral diseases as IHNV at commercial level in Canada against VHSV at experimental level are both success stories. DNA vaccination strategies against many other viral diseases have, however, not yet yielded sufficient results
L. B. Hølvold, A. Myhr, R. Dalmo
semanticscholar   +1 more source

Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside [PDF]

, 2013
Chapter 12 in Novel Gene Therapy ...
Brooks, Suzanne E., Denniss, Frances, Guinn, Barbara-Ann, Khan, Ghazala, Sigurdardottir, Dagmar   +4 more
core   +3 more sources